Biomark Diagnostics Statistics

Total Valuation

Biomark Diagnostics has a market cap or net worth of CAD 14.78 million. The enterprise value is 16.22 million.

Market Cap	14.78M
Enterprise Value	16.22M

Important Dates

The next estimated earnings date is Wednesday, February 26, 2025.

Earnings Date	Feb 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.88%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	39.08M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.24
EV / Sales	103.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.77

Financial Position

The company has a current ratio of 0.07

Current Ratio	0.07
Quick Ratio	0.07
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.26
Interest Coverage	-26.81

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-168.69%
Return on Capital (ROIC)	-325.61%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.21
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.57% in the last 52 weeks. The beta is -0.46, so Biomark Diagnostics's price volatility has been lower than the market average.

Beta (5Y)	-0.46
52-Week Price Change	-28.57%
50-Day Moving Average	0.21
200-Day Moving Average	0.24
Relative Strength Index (RSI)	40.28
Average Volume (20 Days)	725

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biomark Diagnostics had revenue of CAD 158,009 and -1.97 million in losses. Loss per share was -0.02.

Revenue	158,009
Gross Profit	158,009
Operating Income	-2.04M
Pretax Income	-1.97M
Net Income	-1.97M
EBITDA	-2.02M
EBIT	-2.04M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 34,645 in cash and 1.49 million in debt, giving a net cash position of -1.45 million.

Cash & Cash Equivalents	34,645
Total Debt	1.49M
Net Cash	-1.45M
Net Cash Per Share	n/a
Equity (Book Value)	-1.03M
Book Value Per Share	-0.01
Working Capital	-1.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.17 million and capital expenditures -5,945, giving a free cash flow of -1.18 million.

Operating Cash Flow	-1.17M
Capital Expenditures	-5,945
Free Cash Flow	-1.18M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,289.69%
Pretax Margin	-1,245.91%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Biomark Diagnostics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.88%
Shareholder Yield	-0.88%
Earnings Yield	-11.06%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biomark Diagnostics has an Altman Z-Score of -26.83. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-26.83
Piotroski F-Score	n/a